Posted by Michael Wonder on 23 May 2019
Health economic assessment of Tegsedi in hereditary transthyretin amyloidosis
17 May 2019 - TLV has produced a health economic knowledge base for the regions for Tegsedi (inotersen) that treat hereditary transtyretin amyloidosis also called Skellefte Disease with disability in peripheral nerves, so-called stage 1 or 2 polyneuropathy.
TLV believes that the best possible nursing care is standard treatment for patients with Skellefte Disease and thus is the most relevant comparison alternative for Tegsedi.
TLV believes that the uncertainties in the health economic analyses are very high when Tegsedi is compared to the best possible care. The uncertainties include the risk of suffering from various disease states, mortality, adherence to treatment, treatment interruptions in clinical practice and costs.
TLV estimates the cost per won quality-adjusted year of life with Tegsedi compared with the best possible care for about SEK 4.9 million.
